The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Cancer models developed with 3D bioprinting technology allow for rapid evaluation of individual drug responses.

Principal Financial Group Inc. acquired a new position in Zai Lab Limited (NASDAQ:ZLAB – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 1,762,954 ...

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, is approaching a critical juncture in its development ...